The Laboratory of Pathology, Center for Cancer Research (CCR) of the National Cancer Institute (NCI), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), Bethesda, MD, is actively recruiting for a molecular pathologist to participate in the Laboratory of Pathology’s expanding clinical cancer genomics program. In particular, this individual will contribute to the direction of next-generation sequencing and/or genome-wide array-based clinical platforms. This position represents an effort to augment the current capabilities in molecular diagnostics and to build on the Laboratory of Pathology’s growing interest and expertise in clinical cancer genomics and precision diagnostics. This is an exciting opportunity for an individual with interests and expertise in the application of next-generation sequencing and genome-wide array-based approaches in the clinical setting of diagnostic pathology. Current clinical NGS platforms include a 500-gene panel (TSO-500), whole-transcriptome RNAseq for fusion detection, and whole exome sequencing for somatic mutations. Plans are also underway to validate a 500-gene liquid biopsy assay for clinical reporting. We have an active methylation array clinical diagnostics program for CNS tumors, to be expanded into additional tumor types. Integration of molecular alterations within the context of standard anatomic pathology diagnostic workflow represents an exciting direction that is being vigorously pursued by the Laboratory of Pathology and provides many opportunities for clinical genomics and investigative pursuits by the successful applicant.
About NCI's Center for Cancer Research
The CCR is an intramural research component of the NCI. CCR’s enabling infrastructure facilitates clinical studies at the NIH Clinical Center, the world’s largest dedicated clinical research complex, and provides extensive opportunities for collaboration with other investigators at the forefront of medical research. This environment enables scientists and clinicians to undertake high-risk, high-impact, laboratory- and clinic-based investigations. Investigators are supported by a wide array of intellectual, technological, and research resources, including a state-of-the-art computer cluster that supports our informatics workflow. For an overview of CCR, please visit http://ccr.cancer.gov/.
Candidates will be evaluated on their educational background, scholarly work, leadership and mentoring activities, and experience. Salary will be commensurate with education and experience. Candidates may be U.S. citizens, U.S. permanent residents, or those eligible for a visa that will enable work in the U.S.
Please submit curriculum vitae and statement of clinical and research interests and future plans to: email@example.com
The position will remain open until filled.
DHHS, NIH, and NCI are Equal Opportunity Employers. The NIH and NCI are dedicated to building a diverse community in its training and employment programs.
The ideal candidate will have an MD and/or PhD, will be clinically trained in pathology or genetics, and will be board certified/board eligible by the American Board of Pathology or the American Board of Medical Genetics and Genomics. Practical experience in sign-out and development of next generation sequencing or genome-wide array-based assays will be prioritized. Individuals at all levels of experience are welcome to apply, and leadership activities in our molecular diagnostic program will be based on interests and experience of the candidate. This individual will work closely with other molecular pathologists as well as surgical pathologists, clinical oncologists and cancer biologists to help drive the correlative studies that will be an essential component of integrated clinical cancer genomic analyses. This is an exciting opportunity to join a growing trans-institutional, translational research team that will promote and support collaborations across the basic, translational, and clinical research spectrum as the field of diagnostic pathology navigates through the genomic era.
The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training. Established under the National Cancer Institute Act of 1937, NCI is part of the National Institutes of Health (NIH), one of 11 agencies that make up the Department of Health and Human Services (HHS).
NCI’s mission is to lead, conduct, and support cancer research across the nation to advance scientific knowledge and help all people live longer, healthier lives.
As the leader of the cancer research enterprise, collectively known as the National Cancer Program, and the largest funder of cancer research in the world, NCI manages a broad range of research, training, and information dissemination activities that reach across the entire country, meeting the needs of all demographics—rich and poor, urban and rural, and all racial/ethnic populations.